MicuRx Pharmaceuticals, Inc.
  • About MicuRx
    • Our company
    • Our Team
    • Vision & mission
    • History
    • Contact Us
  • Scientific research
    • Antibiotic Resistance
    • Kidney Disease
    • MicuRx R&D
    • Publications
  • Pipeline
  • Newsroom
    • Corporate news
  • Careers
  • Contact Us
  • 中
  • Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients

    Time:2020-05-07  /  View:698 times
    Prev: Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis
    Next: Evaluation of the Effect of Contezolid (MRX-I) on the Corrected QT Interval in a Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study in Healthy Chinese Volunteers
    Back

    Copyright © 2025 All Rights Reserved MicuRx

    Medical Representative Recordation Platform 沪ICP备12020812号

    MicuRx Pharmaceuticals, Inc.
    • About MicuRx
      • Our company
      • Our Team
      • Vision & mission
      • History
      • Contact Us
    • Scientific research
      • Antibiotic Resistance
      • Kidney Disease
      • MicuRx R&D
      • Publications
    • Pipeline
    • Newsroom
      • Corporate news
    • Careers
    • Contact Us